http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105264071-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 |
filingDate | 2014-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2020-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2020-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-105264071-B |
titleOfInvention | SDF-1 delivery for the treatment of ischemic tissue |
abstract | The present invention provides for the treatment of a subject's myocardial tissue by direct administration to or local expression therein of an effective amount of stromal cell-derived factor-1 (SDF-1) to a debilitated, ischemic, and/or peri-infarct region of the subject's myocardial tissue. A method for cardiomyopathy in a subject in an amount that results in a functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular diameter, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) ) cardiac function classification. The present invention also provides a method for treating critical limb ischemia in a subject, namely administering a DNA plasmid encoding human SDF-1 by direct injection into the affected limb. |
priorityDate | 2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 439.